Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6725755 | 0.93 | PTGS2 (0.39) | PTGS2GRM2PAX8 | |
| SCHEMBL6722674 | 0.92 | PTGS2 (0.44) | PTGS2GRM2PAX8MEN1NPC1 | |
| SCHEMBL6718609 | 0.92 | BRD4 (0.39) | PTGS2GRM2PAX8MEN1NPC1 | |
| SCHEMBL6733631 | 0.90 | PTGS2 (0.40) | PTGS2GRM2PAX8MEN1NPC1 | |
| SCHEMBL6734692 | 0.89 | PTGS2 (0.36) | PTGS2GRM2PAX8 | |
| SCHEMBL6718900 | 0.88 | PAX8 (0.46) | PTGS2PAX8MEN1NPC1KMT2A | |
| SCHEMBL6722942 | 0.87 | PTGS2 (0.44) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6722074 | 0.87 | PTGS2 (0.48) | PTGS2GRM2PAX8MEN1NPC1 | |
| SCHEMBL6725361 | 0.86 | PTGS2 (0.50) | PTGS2 | |
| SCHEMBL6723142 | 0.86 | PTGS2 (0.43) | PTGS2PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885GRM2 893/4885PAX8 3383/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885GRM2 814/4885PAX8 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.